Aricept dominates newly diagnosed Alzheimer's disease patient share

Aricept dominates newly diagnosed Alzheimer's disease patient share

Physician familiarity and a better side effect and safety profile are among the factors leading to high Aricept prescription rates, according to a report from Decision Resources. The Eisai/Pfizer drug has a 42.4% patient share for first-line treatment for newly diagnosed Alzheimer's disease, the report says. That's compared to Novartis's Exelon, which has a 2.8% share, and Shire/Janssen/Ortho-McNeil's Razadyne with a 1.4% share. The patient share data is from a report that's part of Decision Resources' Treatment Algorithms Insight Series. The reports in the series examine different diseases and provide qualitative diagnosis and referral patterns, quantitative treatment algorithms, physician opinions, and other data.